Menu
  • Home
  • About
    • Our Mission
    • Our Team
  • Science
    • CAR-γδ T Cell
    • iPSC-γδ NKT Cell
    • Publications
  • Pipeline
  • Manufacturer
  • Investors
    • Stock Info
    • Press Releases
  • Contact Us

Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers

« Expansion of gamma delta T cells – a short review on bisphosphonate and K562-based methods Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis »
cytomed
  • Email:

    enquiry@cytomed.sg

    Phone:

    +607-3824911
  • Quick Links

      • Home
      • About Us
      • Publications
      • Contact Us

    Let's Get Connected!

  • CytoMed Therapeutics Pte Ltd (201808327H)

    Registered Office:

    21 Bukit Batok Crescent, #17-80 WCEGA Tower, Singapore 658065

    CytoMed Therapeutics (Malaysia) Sdn Bhd (1074609-M)

    Registered Office:

    Room 503 5th Floor, Merlin Tower, Jalan Meldrum 80000 Johor Bahru, Malaysia

  • © 2021 CytoMed Therapeutics Pte Ltd

    Designed & Developed by Klizo Solutions Pvt. Ltd.